Vidaza: profile and news

Pharmion Announces Start of Phase 1 Trial Evaluating Satraplatin ...  17 May 2006
Pharmion has a number of products on the market including the world's first approved epigenetic cancer drug, Vidaza(R), a DNA demethylating agent. ... - PharmaLive.com (press release),

Pharmion Corporation Announces Q1 2006 Financial Results  Apr 27, 2006
Sales of Vidaza® (azacitidine for injectable suspension) totaled $32.9 million in the first quarter of 2006, compared to $27.5 million in the year- ago quarter ... - Yahoo! News (press release)

PHARMION CORPORATION ANNOUNCES Q1 2006 FINANCIAL  Apr 27, 2006
Sales of Vidaza(R) (azacitidine for injectable suspension) totaled US$32.9 million in the first quarter of 2006, compared to US$27.5 million in the year-ago ... - ITNews,

MGI Pharma wins FDA OK for blood disorder drug  May 3, 2006
Dacogen will compete with Pharmion Corp.'s (PHRM.O: Quote, Profile, Research) Vidaza, which was approved in the United States in 2004. ... - Reuters

Aranesp® Effective for Treating Anemia Associated with ‘Low ...  May 12, 2006
More recently two drugs, Vidaza® (5-azacytidine) and Dacogen® (decitabine) have been approved by the US Food and Drug Administration as specific therapy for ... - Cancer Consultants (press release),

FDA OKs Bone Marrow Disorders Drug  May 3, 2006
BV Haarlem for MGI Pharma Inc. of Bloomington, Minn. Other drugs to treat myelodysplastic syndromes include Vidaza and Revlimid. - CBS News

SuperGen, MGI Pharma get FDA approval for MDS drug  May 4, 2006
...of Summit, New Jersey, was approved in December 2005. The FDA approved the first MDS drug, Vidaza, in 2004. That drug was developed by Pharmion Corp. ... - Bizjournals.com,

Dacogen receives federal support  May 4, 2006
...the market first. Both drugs compete with Pharmion Corp.'s Vidaza in the market that analysts say may top $300 million. "This is ... - Inside Bay Area,

MethylGene Announces First Quarter 2006 Results  May 5, 2006
Continued enrolment in Phase I cancer monotherapy trials, and a Phase I/II combination trial with Vidaza® (azacitidine, marketed by Pharmion) for MGCD0103. ... - Market Wire (press release)